EQL Pharma licenses Memprex to Pharmacenter for Hungary market

Reuters2026/08/12 06:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

EQL Pharma licensed exclusive rights to sell Memprex (methenamine hippurate) in Hungary to local drugmaker Pharmacenter.
Deal includes three milestone payments totaling a five-digit amount in EUR, conditional on meeting agreed sales targets.
EQL will supply the product to Pharmacenter at a transfer price.
Hungary currently has no methenamine hippurate product on the market; Memprex targets prophylaxis for recurrent urinary tract infections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202608120234BITN____UKPR__SV_20260812-BIT-6655-0) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

EQL Pharma licenses Memprex to Pharmacenter for Hungary market

You may also like

Crypto prices